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Abstract
Our understanding of arrhythmogenic
right ventricular cardiomyopathy (ARVC)
has advanced considerably over the past 30-
40 years. This is an inherited cardiomyopa-
thy with complicated genetic inheritance
and variable penetrance. Desmosomal dys-
function underlies most cases, and appreci-
ating this pathophysiology has contributed
to patient management, particularly with
respect to exercise restriction to reduce dis-
ease progression. The diagnosis is made
according to a series of Task Force Criteria,
and subsequent management is guided by
expert consensus in the absence of compar-
ative data. ARVC is associated with sudden
cardiac death (SCD), particularly in young
athletic individuals who unknowingly har-
bour the condition. Risk stratification is
important to guide implantable cardiovert-
er-defibrillator use and reduce SCD.
Residual gaps in our understanding, partic-
ularly surrounding incomplete penetrance,
the underlying pathophysiology and risk
stratification, are being targeted by collabo-
rative efforts, large registries, prospective
studies and translational research.
Introduction
Arrhythmogenic right ventricular car-
diomyopathy (ARVC) is an inherited car-
diomyopathy associated with syncope, ven-
tricular arrhythmias (VA) and sudden car-
diac death (SCD).1 Early descriptions of the
condition were based on small numbers of
severely affected individuals with signifi-
cant arrhythmic events and heart failure.2,3
We now have an increased understanding of
the phenotypic breadth of this condition,
through systematic diagnostic testing
(including deep phenotyping with both
imaging and electrical evaluation) coupled
with family screening and genetic testing.
Desmosomal dysfunction causes disease in
most patients and a pathogenic mutation
can be identified in approximately 60% of
those affected.4,5 Although inheritance is
usually autosomal dominant, there is vari-
able penetrance and some affected individ-
uals may demonstrate a mild and even
absent phenotype. 
Epidemiology
ARVC has an estimated prevalence of 1
in 1000 to 1 in 5000; higher in European
countries such as Italy and Germany.6
Patients typically present between the sec-
ond and fifth decade. It is unusual for clini-
cal signs and symptoms to occur younger
than 12 or older than 60 years of age.5,7
Phenotypic expression is more prevalent in
males than females, and male subjects
appear more likely to develop severe dis-
ease and arrhythmic events.8,9 In some cases
this sex difference relates to genotype. For
example, males carrying the S358L muta-
tion in TMEM43 develop lethal VA at a
younger age than their female counter-
parts.10
ARVC is an important cause of SCD in
the young, particularly in young athletes,
where events frequently occur during exer-
cise.11,12 Competitive sport is associated
with earlier ARVC presentation and an
increased risk of fatal arrhythmias.13 SCD
may occur in the absence of clear pheno-
type and remote ARVC diagnoses have
been made in some sudden unexplained
death victims only by family screening and
molecular autopsy.14
Genetics
Inheritance is most commonly autoso-
mal dominant, but incomplete penetrance
may obscure Mendelian patterns.15 ARVC is
associated with mutations in genes encod-
ing desmosomal proteins, most commonly
plakophilin-2 [PKP2], desmoglein-2
[DSG2], desmoplakin [DSP] and desmo-
collin-2 [DSC2](Table 1).16-18 Compound
and digenic heterozygosity are frequent and
likely contribute to variable penetrance and
the complexity of inheritance patterns.19
Increased penetrance and more severe dis-
ease have been associated with multiple
mutations.20 Autosomal recessive forms are
rare. These include cardiocutaneous syn-
dromes Naxos and Carvajal disease, where
cardiomyopathy is found in association
with palmoplantar keratoderma and woolly
hair.21,22 Causal mutations in extra-desmo-
somal genes have also been described.
These include a Newfoundland founder
population with the S358L mutation in
TMEM43 which causes a fully penetrant
aggressive form of the disease with high
incidence of SCD and heart failure.23
Genotype-phenotype correlations
Patients with multiple mutations have
earlier occurrence of ventricular arrhyth-
mias and higher rates of LV dysfunction and
cardiac transplantation.24 Heart failure with
LV dysfunction is more frequently associat-
ed with DSP than PKP2 mutations and LV
involvement appears more marked in fami-
lies with chain terminating mutations.24-26
Patients with PKP2 variants may have ear-
lier onset of symptoms and VA.27 Overall,
missense mutation carriers appear to have
similar outcomes compared with truncating
and splice site mutation carriers.24 However,
there is significant variation within
families.28
Pathophysiology
Histopathology demonstrates patchy
lymphocytic infiltrates, myocyte death and
fibrofatty replacement of ventricular
myocardium starting in the epicardial and
midmyocardial layers. This leads to wall
thinning and aneurysmal dilatation. The
classical pattern of disease affects the right
ventricle (RV) with structural changes fre-
quently located in the subtricupsid region,
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right ventricular outflow tract (RVOT) and
apex.29 This distribution is known as the tri-
angle of dysplasia. Non-classical patterns of
disease, with biventricular involvement and
isolated left ventricular (LV) disease, are
increasingly recognised with advances in
imaging.30 Renaming the condition arrhyth-
mogenic cardiomyopathy has consequently
been suggested.25
Desmosomal dysfunction appears to be
the common final pathway for most ARVC
cases. Healthy desmosomes reside within
the intercalated disc. These desmosomes
provide mechanical continuity between
myocytes and mediate intracellular and
intercellular signal transduction.31 Electron
microscopy studies have demonstrated
remodelling of the intercalated disc and
desmosomal loss in myocardial biopsies
from ARVC patients.32 Immunohisto -
chemical studies have shown that mutant
desmosomal proteins shift from the interca-
lated disc into the cell cytoplasm and nucle-
us causing changes in nuclear signalling
and gene transcription.33 Animal studies
have suggested that genetically determined
desmosomal abnormalities disrupt intercel-
lular junctions, leading to myocyte detach-
ment and eventual loss. Furthermore,
increased expression of adipogenic and
fibrogenic genes resulting from changes in
nuclear signalling and gene transcription
contributes to fibrofatty scarring.34,35
Mechanical stress appears to worsen
desmosomal dysfunction. This may partly
explain why adverse outcomes are more
common in athletes with ARVC and why
exercise accelerates RV dysfunction in
mouse models of disease.36,37
Within the intercalated disc, the desmo-
some interacts with sodium channels (Nav
1.5) and gap junction proteins (connexin
43) to regulate adhesion, excitability and
cell-to-cell coupling. This network of pro-
teins is known as the connexome.31
Ventricular arrhythmias in ARVC appear to
result from slowed cardiac conduction cre-
ating macro-reentry circuits. This may
occur through areas of scar and/or as a
result of gap junction remodelling leading
to decreased connexin 43 and reduced sodi-
um current.38,39 This latter theory may
underlie the clinical overlap with the
Brugada syndrome observed in some
cases.40
TMEM43 is a nuclear membrane pro-
tein which may form part of an adipogenic
pathway.23 Murine cell studies have shown
that the S358L missense mutation alters the
localisation of intercalated disc proteins,
changes gap junction function and reduces
conduction velocity.41 However, the mecha-
nism by which this pathogenic variant caus-
es ARVC is poorly understood at present.
Clinical presentation and natural
history
Symptoms are usually due to VA and
include palpitations, lightheadedness, syn-
cope, cardiac arrest and SCD.5 SCD is an
important, but uncommon, first presentation
in some young adults, particularly athletes
harbouring the condition.3 In diagnosed and
treated ARVC patients, the long-term out-
come is favourable with low rates of SCD,
cardiac transplantation and cardiac mortali-
ty.5,24 Different phases are described in
ARVC disease progression: the early con-
cealed phase where individuals are usually
asymptomatic but still at risk from SCD; the
overt electrical phase where individuals
present with arrhythmias but structurally
normal hearts by conventional imaging; the
structural phase where individuals exhibit
ventricular morphological abnormalities;
and rarely diffuse progressive disease with
RV, LV or biventricular heart failure.42 Left
ventricular involvement was previously
thought to develop in the later stages of dis-
ease, but the advent of contrast enhanced
CMR and genetic testing has shown that in
some patients, particularly those with DSP
mutations, LV disease occurs early and may
be dominant or isolated.24,25,30 Electrical
changes do appear to pre-date structural dis-
ease however. When diagnosing ARVC,
abnormal imaging with a completely nor-
mal ECG should be considered suspicious
and warrants careful review.43
Diagnosis
There is no single gold standard investi-
gation for ARVC. Diagnosis is made accord-
ing to a series of Task Force criteria (TFC).1
These comprise data from cardiac imaging,
electrocardiography, endomyocardial biopsy
(when performed), family history and genetic
testing. Categories include major and minor
criteria (equivalent to 2 points and 1 point
respectively). Patients may be classified as
definitely affected, borderline or possibly
affected depending on the number of points
they accumulate. A definite diagnosis
requires four points (Table 2). The original
1994 TFC were based on clinical experience
in patients with severe disease.44 These were
highly specific but lacked sensitivity for the
diagnosis of an early phenotype. In addition,
qualitative analysis of CMR data resulted in
ARVC over-diagnosis.45 The TFC were
revised in 2010 to improve diagnostic sensi-
tivity, albeit in the absence of a gold-standard.
Revised TFC included genetic criteria, new
electrical parameters and quantification of
cardiac imaging.1 This led to increased ARVC
diagnosis in familial disease and for carriers
of desmosomal mutations, but reduced num-
bers of patients fulfilling CMR criteria, creat-
ing a subgroup who no longer satisfied TFC
and have subsequently had their ARVC diag-
nosis removed.46 Unfortunately some patients
underwent ICD implantation based on his-
toric misinterpretation of CMR studies or
overtreatment of benign outflow tract form of
ventricular tachycardia.47
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Table 1. Arrhythmogenic right ventricular cardiomyopathy (ARVC) associated genes.
Genotype          Gene                 Locus                         Protein                          % of disease*
ARVC 1                    TGFB3                     14q24.3        Transforming growth factor-beta 3                         -
ARVC 2                     RYR2                        1q43                Cardiac ryanodine receptor                               -
ARVC 3                 Unknown               14q12-q22                                    -                                                        -
ARVC 4                      TTN                   2q32.1-q32.3                               Titin                                                    -
ARVC 5                  TMEM43                    3p25.1               Transmembrane protein 43                               -
ARVC 6                 Unknown               10p14-p12                                    -                                                        -
ARVC 7                       DES                          2q35                                   Desmin                                                 -
ARVC 8                       DSP                          6p24                             Desmoplakin°                                     2%-12%
ARVC 9                      PKP2                        12p11                             Plakophilin-2                                     25%-40%
ARVC 10                   DSG2                      18q12.1                           Desmoglein-2                                     5%-10%
ARVC 11                   DSC2                      18q12.1                          Desmocollin-2                                      2%-7%
ARVC 12                     JUP                       17q21.2                            Plakoglobin#                                             -
Other                         PLN                        6q22.1                          Phospholamban                                         -
                                 LMNA                        1q22                                 Lamin A/C                                               -
                                 SCN5A                       3p21                    Cardiac sodium channel                                  -
                               CTNNA3                   10q22.2                         Alpha-T-catenin                                          -
*% of disease included where >5%; °recessive form: Carvajal syndrome; #recessive form: Naxos disease.
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Electrocardiographic features and
ventricular arrhythmias
Electrocardiographic (ECG) features
include repolarization (T-wave inversion;
TWI) and depolarization (epsilon waves,
terminal activation delay of the QRS com-
plex) abnormalities.48 TWI and epsilon
waves are associated with diffuse disease
and found less commonly in early, localised
ARVC.48 VA include variable frequency of
ventricular ectopy and ventricular tachycar-
dia, which may degenerate into ventricular
fibrillation (Figure 1). VA are often trig-
gered by exercise and exercise testing may
reveal latent disease.3,49 ECG changes are
classically seen in the right precordial leads
(V1-V3), with extent of changes incorporat-
ed into major or minor TFC. Right ventric-
ular related VA have a left bundle branch
block (LBBB) morphology, with a variable
axis depending on the origin or exit of the
arrhythmia. In left dominant disease, ECG
changes are found in the inferolateral leads
and VA have right bundle branch block
morphology.30 Late potentials on signal-
averaged ECG are thought to represent
depolarization abnormalities secondary to
slowed conduction, due to myocardial scar.
Although late potentials are associated with
other myocardial pathologies, these have
high diagnostic sensitivity and specificity
when ARVC patients are compared with
controls.50
Cardiac imaging
CMR is the preferred diagnostic imaging
technique.43 It is the gold standard for cardiac
volume and function assessment. Tissue
characterisation, including late gadolinium
enhancement (LGE) provides incremental
information regarding myocardial fibrofatty
scar.51 Echocardiography allows longitudinal
assessment of ventricular function, particu-
larly for patients with implantable-car-
dioverter defibrillators (ICD) in situ, where
CMR may be contraindicated (Figure 2).
Original TFC for imaging, including
myocardial fatty infiltration, were qualitative
and resulted in over-diagnosis.44,45 When the
TFC were revised, imaging parameters were
quantified and CMR assessment of myocar-
dial fat was no longer recommended (Table
2).1 Classical disease causes RV regional
wall motion abnormalities (RWMA) with
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Table 2. Revised 2010 Task Force Criteria (TFC) for arrhythmogenic right ventricular cardiomyopathy (ARVC) diagnosis. 
                                                  Major criteria                                                            Minor criteria
Global or regional dysfunction         2D echo: Regional RV akinesia, dyskinesia or                          2D echo: Regional RV akinesia, dyskinesia or aneurysm
and structural alterations                  aneurysm and 1 of the following (end diastole):                  and 1 of the following (end diastole):
                                                                      - PLAX RVOT ≥32mm (≥19 mm/m2)                                           - PLAX RVOT ≥29 to <32mm (≥16 to <19 mm/m2)
                                                                      - PSAX RVOT ≥36mm (≥21 mm/m2)                                           - PSAX RVOT ≥32 to <36mm (≥18 to <21 mm/m2)
                                                                      - Fractional area change ≤33%                                                    - Fractional area change >33% to ≤40%
                                                                 MRI: Regional RV akinesia or dyssynchronous                       MRI: Regional RV akinesia or dyssynchronous RV 
                                                                 RV contraction and 1 of the following:                                       contraction and 1 of the following:
                                                                      - RV end-diastolic volume ≥110 ml/m2 (male)                        - RV end-diastolic volume ≥100 to  <110 ml/m2 (male)
                                                                      or ≥100ml/m2 (female)                                                                 or ≥90 to <100 ml/m2 (female)
                                                                 RV angiography:                                                                                   
                                                                      - Regional RV akinesia, dyskinesia or aneurysm                     
Tissue characterization of wall         Residual myocytes <60% by morphometric analysis            Residual myocytes 60% to 75% by morphometric analysis 
                                                                 (or <50% if estimated) with fibrous replacement                (or 50% to 60% if estimated) with fibrous replacement of the
                                                                 of the RV free wall myocardium in ≥1 sample                        RV free wall myocardium in ≥1 sample with or without fatty
                                                                 with or without fatty replacement of tissue                            replacement of tissue on endomyocardial biopsy
                                                                 on endomyocardial biopsy                                                            
Repolarization abnormalities            ECG:                                                                                                  ECG:
                                                                 - Inverted T waves in right precordial leads (V1-V3)              - Inverted T waves in leads V1-V2 in individuals >14 years
                                                                 or beyond in individuals >14 years of age                               of age (in the absence of complete RBBB) or in leads V4, V5, V6
                                                                 (in the absence of complete RBBB with QRS ≥120ms)       - Inverted T waves in leads V1-V4 in individuals >14 years
                                                                                                                                                                             of age in the presence of complete RBBB
Depolarization/conduction                ECG: Epsilon wave (reproducible low-amplitude signals     SAECG: late potentials in ≥1 of 3 parameters in the absence of 
abnormalities                                        between end of QRS complex to beginning of T wave)       QRS duration ≥110ms on ECG:
                                                                 in leads V1, V2 or V3                                                                                                                                  - Filtered QRS duration ≥114ms
                                                                                                                                                                                  - Duration of terminal QRS <40 μV ≥38 ms
                                                                                                                                                                                  - Root-mean-square voltage of terminal 40 ms ≤20 μV
                                                                                                                                                                             ECG: Terminal activation duration of QRS ≥55 ms measured
                                                                                                                                                                             from the nadir of the S wave to the end of the QRS (including
                                                                                                                                                                             R’) in leads V1, V2 or V3 in the absence of complete RBBB
Arrhythmias                                           VT of LBBB morphology with superior axis                             RVOT configuration VT of LBBB morphology with inferior axis
                                                                 (negative or indeterminate QRS in leads II, III                      (positive QRS in leads II, III and aVF and negative in aVL) or 
                                                                 and aVF and positive in aVL)                                                       unknown axis
                                                                                                                                                                             Holter: >500 ventricular ectopics/24 hours
Family history                                        ARVC confirmed in a first-degree                                              ARVC in a first-degree relative in whom it is not possible to 
                                                                 relative who meets current TFC                                                 determine whether the family member meets current TFC 
                                                                 ARVC confirmed pathologically at autopsy                               Premature sudden death (<35 years of age)
                                                                 or surgery in a first-degree relative                                          due to suspected ARVC in a first-degree relative 
                                                                 Identification of a pathogenic mutation*                                 ARVC confirmed pathologically or by 
                                                                 categorized as associated or probably associated                current TFC in a second-degree relative 
                                                                 with ARVC in the patient under evaluation                              
PLAX parasternal long-axis view; RVOT, right ventricular outflow tract; PSAX, parasternal short-axis view; RBBB, right bundle branch block; VT, ventricular tachycardia. Diagnostic terminology for revised criteria: definite
diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different
categories.  *A pathogenic mutation is a DNA alteration associated with ARVC that alters or is expected to alter the encoded protein, is unobserved or rare in a large non-ARVC control population, and either alters or
is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree. Adapted from Marcus et al., 2010.1
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RV dilatation and/or impairment. CMR has
higher accuracy for the detection of subtle
RV abnormalities when compared with
echocardiography.43 In left dominant disease,
there may be LV RWMA with LV dilatation
and/or impairment. LGE in the LV is usually
subepicardial or midmyocardial (Figure
3).25,30 There are no diagnostic imaging crite-
ria for left dominant disease.1 As a result, iso-
lated LV disease may be attributed to
myocarditis, biventricular disease may be
confused with dilated cardiomyopathy
(DCM), and as a result LV dominant forms
are likely underdiagnosed.30
Genetic testing
In clinical practice, genetic evaluation
is used for confirmatory testing in index
cases and cascade screening in families.16 A
pathogenic mutation can be identified in
approximately 60% of index cases.4,5
Comprehensive or targeted screening of the
ARVC genes can be useful for patients sat-
isfying TFC and mutation specific screen-
ing is recommended for family members
after identification of the causative muta-
tion in an index case.16 Interpretation of
ARVC genetic tests should be made by
expert centres as judging the pathogenicity
of a variant (particularly missense variants)
can be challenging.16 Emergence of new
data has led to reclassification of variants
over time.52 Frequent compound and
digenic heterozygosity suggests many vari-
ants alone are not sufficient for clinical dis-
ease and some rare variants have been
found in healthy populations at rates high
enough to downgrade the variant status
from pathogenic to disease modifier or
benign.19,52,53 Novel unique familial muta-
tions are also common and these require
robust determination of causality.54
Differential diagnoses
ARVC has mimics including idiopathic
RVOT tachycardia, athletic heart, DCM,
cardiac sarcoid, Chagas and congenital heart
disease causing RV volume overload.
Idiopathic RVOT tachycardia also presents
with LBBB morphology VA but has a
benign prognosis. The ECG morphology of
ARVC-related VA have significant overlap
with benign RV arrhythmias and cannot be
distinguished by ECG morphology alone,
although ECG features suggesting an RV
free-wall origin should raise the index of
suspicion of ARVC. Presence of RV struc-
tural abnormalities favours ARVC over idio-
pathic RVOT tachycardia, but absence of
structural disease does not exclude it. Data
suggest that VA with broader QRS, increas-
ing notching and axis <30° are highly sug-
gestive of ARVC.55-58 CMR has an important
role for identification of phenocopies
including DCM, cardiac sarcoid and RV vol-
ume overload.59 Left dominant ARVC may
mimic DCM but frequent arrhythmias and
subepicardial LGE on CMR favour ARVC
diagnosis.43 Cardiac sarcoid may present
with TWI in ECG leads V1-V3, ventricular
arrhythmias and RV structural abnormali-
ties. A combined diagnostic approach
including CMR, FDG PET-CT and endomy-
ocardial biopsy (with electroanatomic volt-
age mapping to improve diagnostic yield)
may be required for correct diagnosis when
cardiac sarcoid is suspected.60,61
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Figure 2. Echocardiography in patients with arrhythmogenic right ventricular cardiomy-
opathy (ARVC) demonstrates right ventricular apical aneurysms in the four-chamber
view (panel A), and right ventricular dilatation in the parasternal short axis (PSAX; panel
B) and parasternal long axis (PLAX; panel C) views.
Figure 1. Electrocardiographic (ECG) features in arrhythmogenic right ventricular car-
diomyopathy (ARVC). Panel (A) demonstrates T wave inversion in the right precordial
ECG leads V1-V3. Panel (B) demonstrates onset of left bundle branch block ventricular
tachycardia with superior axis during exercise.
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Sudden death risk
Increased risk of SCD appears to be
associated with male gender, proband sta-
tus, unexplained cardiac syncope, competi-
tive and endurance exercise, extensive
structural disease, electrical instability (VA
and/or frequent ventricular ectopy) and
multiple pathogenic variants or a mutation
in TMEM43.13,20,23,24,62-66 The prognostic
value of programmed ventricular stimula-
tion in asymptomatic patients with ARVC
remains unclear, but invasive evaluation of
myocardial scar and fragmented, delayed
electrograms may provide incremental
information regarding SCD risk.63,64,67
ICD therapy reduces SCD in high-risk
patients with ARVC, but ICD implantation
carries risks of complication, particularly
lead-related adverse events and inappropri-
ate shocks in younger patients.64,68,69
Therefore, accurate risk stratification and
appropriate patient selection is important.
Newer subcutaneous ICD (S-ICD) technol-
ogy represents progress towards a less inva-
sive approach in selected patients without
pacing indications. This appears safe and
efficacious and may reduce complications
related to transvenous leads. Not all patients
are suitable however, and must be carefully
screened. In addition inappropriate shock
rates remain high and performance data is
limited at present.70
Management
Patient management involves measures
to decrease symptoms and disease progres-
sion, to protect against SCD and to organise
family screening. Data regarding patient
management and risk stratification in
ARVC come from single centre reports and
small multicentre registries.71 Patients with
ARVC should be evaluated every 1-2 years.
Measures to decrease symptoms and
reduce ICD therapies
Antiarrhythmic drug therapy may
improve quality of life by reducing sympto-
matic VA. Beta-blockers, sotalol and amio-
darone are used. A combination of amio-
darone with a beta-blocker appears most
effective, but cumulative side effects limit
long-term use of amiodarone in young
patients.72 In patients with sustained
monomorphic VT, invasive electrophysio-
logical voltage mapping can identify areas
of scar and guide catheter ablation of VA.
This is more successful when epicardial and
endocardial approaches are combined
(Figure 4).73 Due to the progressive nature
of disease, there may be recurrences but
recent data suggests good outcomes, partic-
ularly reduction in long-term amiodarone
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Figure 3. Cardiac magnetic resonance (CMR) imaging demonstrates subepicardial and
midmyocardial left ventricular late gadolinium enhancement in a patient with arrhyth-
mogenic right ventricular cardiomyopathy (ARVC). Panel (A) is a long axis four chamber
image and panels (B) and (C) are short axis views.
Figure 4. Endocardial and epicardial voltage mapping. Panel (A) shows right ventricular
endocardial bipolar voltage maps in the right anterior oblique (RAO) and left anterior
oblique (LAO) views from a 22-year-old patient with arrhythmogenic right ventricular
cardiomyopathy (ARVC) and ventricular tachycardia refractory to amiodarone. Panel (B)
shows epicardial bipolar voltage maps from the same views. Purple reflects healthy
myocardium and red reflects severely scarred myocardium or epicardial fat. Note the
patchy endocardial scar but more extensive epicardial scar. The black or green markers
indicate late potentials (delayed electrical activity within the scar). The red markers are
ablation lesions performed during the procedure.
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therapy.74,75 Heart failure (RV or LV) is
treated with standard pharmacologic thera-
py including angiotensin-converting-
enzyme inhibitors, angiotensin-II receptor
blockers, beta-blockers and diuretics.71
Cardiac transplantation may be considered
in severe disease.76 Anticoagulation is indi-
cated for patients who develop intracardiac
thrombus and/or systemic thromboem-
bolism.71
Measures to decrease disease pro-
gression
Endurance training at a competitive
level has been shown to exacerbate the
ARVC phenotype and therefore avoidance
of high-level endurance training and com-
petitive sports is recommended.
Engagement in recreational sports with low
cardiovascular demand appears accept-
able.77
Reduction of SCD risk
Patients with aborted SCD and sus-
tained VT with haemodynamic compromise
are at highest risk of SCD (up to 10% per
annum) and ICD insertion is
recommended.78 Consensus guidelines
based on extrapolation from other car-
diomyopathies and personal experience also
include severe ventricular dysfunction as a
high-risk feature (RVEF and/or LVEF
≤35%).71 ICD therapy may be considered in
patients with major risk factors including
unexplained syncope, non-sustained VT
and moderate RV and/or LV dysfunction. It
is generally agreed that asymptomatic
patients without risk factors and healthy
gene carriers are at low risk of arrhythmic
events and do not require ICD insertion
(Table 3).71,78 In borderline patients, an
implantable cardiac monitor may be consid-
ered to assess for VA and aid decisions
about subsequent ICD placement.
Family screening and identification
of subtle disease
Family screening comprises clinical and
genetic evaluation. Clinical testing com-
prises ECG, echocardiography and/or
CMR, Holter monitoring and exercise test-
ing, with interpretation of results guided by
the modified TFC (for familial disease).1,71
Definitive genetic diagnosis in an index
case enables cascade screening of family
members. Those who test positive continue
clinical follow-up whereas those who test
negative may be discharged. However,
given the complexities of ARVC genetics
and the uncertainty surrounding patho-
genicity of some variants, caution should be
exercised prior to discharge of gene-nega-
tive relatives.16 Family members and
healthy gene carriers should be evaluated
every 2-3 years.71
Future directions
In a rare disease without randomised
controlled trial data, the evidence base for
guidelines is limited. There are unanswered
questions, particularly surrounding variable
penetrance, the underlying pathophysiology
and risk stratification. Collaborative reg-
istries will help to address this.79
Prospective and multicentre randomised
controlled studies with larger patient
cohorts and longer follow-up are also need-
ed. Therapeutic advances will depend on
improved understanding of the underlying
genetic and molecular mechanisms and
translational work bringing together basic
scientists and clinicians will be important to
further advancement in this area.
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